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Abstract: Background 
The control of breast cell survival is of critical importance for 
preventing breast cancer initiation and progression. The activity of many 
proteins which regulate cell survival is controlled by reversible 
phosphorylation, so that the relevant kinases and phosphatases play 
crucial roles in determining cell fate. Several protein kinases act as 
oncoproteins in breast cancer and changes in their activities contribute 
to the process of transformation. Through counteracting the activity of 
oncogenic kinases, the protein phosphatases are also likely to be 
important players in breast cancer development, but this class of 
molecules is relatively poorly understood. Here we have investigated the 
role of the serine/ threonine protein phosphatase 4 in the control of 
cell survival of breast cancer cells.  
Methods 
The breast cancer cell lines, MCF7 and MDA-MB-231, were transfected with 
expression vectors encoding the catalytic subunit of protein phosphatase 
4 (PP4c) or with PP4c siRNAs. Culture viability, apoptosis, cell 
migration and cell cycle were assessed. The involvement of phosphoprotein 
enriched in astrocytes 15 kD (PEA15) in PP4c action was investigated by 
immunoblotting approaches and by siRNA-mediated silencing of PEA15.  
Results 
In this study we showed that PP4c over-expression inhibited cell 
proliferation, enhanced spontaneous apoptosis and decreased the migratory 
and colony forming abilities of breast cancer cells. Moreover, PP4c down-
regulation produced complementary effects. PP4c is demonstrated to 
regulate the phosphorylation of PEA15, and PEA15 itself regulates the 
apoptosis of breast cancer cells. The inhibitory effects of PP4c on 
breast cancer cell survival and growth were lost in PEA15 knockdown 
cells, confirming that PP4c action is mediated, at least in part, through 
the de-phosphorylation of apoptosis regulator PEA15. 
Conclusion 
Our work shows that PP4 regulates breast cancer cell survival and 
identifies a novel PP4c-PEA15 signalling axis in the control of breast 
cancer cell survival. The dysfunction of this axis may be important in 
the development and progression of breast cancer.  
   
 
 
 
Response to Reviewers: Reviewers’ comments 
Strengths and weaknesses  
We are pleased that the reviewer considers the work to be well 
accomplished and considers it to be worthy of publication.  Please find 
below our response to Reviewers’ Comments. 
•There is a tendency for repetition, which slightly distracted me (see 
comments below). However, this is due to the nature of the subject 
matter. If it can be reduced, that might be useful. I also felt that 
figures 1&2 can be merged, as well as Fig 3&4. A balance has to be struck 
between clarity and space, but the current layout is not too bad. 
Response:  
Two different breast cancer cell lines MCF7 and MDA-MB-231, were used in 
the present study.  The two cell lines were selected because they 
represent different breast cancer phenotypes. MCF-7 is a non-invasive 
cell line that is representative of estrogen-dependent breast cancer, 
whereas MDA-MB-231 is an invasive, estrogen-independent cell line 
representative of triple negative breast cancer (TNBC).  On the one hand, 
MCF7 is the most widely studied of the currently available human breast 
cancer cell lines, hence the reason for its inclusion in the study here. 
On the other hand, there is currently a major need to identify novel 
molecular targets for therapy of TNBC (lacks oestrogen receptor, 
progesterone receptor and HER2 amplification), which can be highly 
malignant and often exhibits resistance to conventional chemotherapies 
[i.e. see Engebraaten et al. (2013)  Am J Pathol 183:1064–1074]; 
consequently we believe that it is also important to include data from 
MDA-MB-231 cells in the full paper. Because the two cell lines are 
representative of different breast cancer subtypes, we do not believe 
that it is justified to merge the various Figures. Indeed the reviewer 
does consider that ‘the current layout is not bad’. 
Minor amendments, typing errors and suggestions for improved syntax: 
We apologise for the typing errors – these have been corrected (Please 
see below). In response to the reviewer’s suggestions, the following 
changes have been made to the manuscript:  
•Page 1, Line 8: The activity of many of proteins 
This now reads: “the activity of many proteins” 
•P 1,  L 34-41: Long sentence. Suggest breaking it in L 34 after the word 
'sequences' AND P 1,  L 39: Missing word 'siRNAs related to ...'? 
This now reads: “ The breast cancer cell lines, MCF7 and MDA-MB-231, were 
transfected with expression vector encoding the catalytic subunit of 
protein phosphatase 4 (PP4c) or with PP4c siRNAs. Culture viability, 
apoptosis, cell migration and cell cycle were assessed.” 
•P 4,  L 1:  Comma between 'HERS' and HER2/Neu 
This now reads: “(HERs), HER2/Neu” 
•P 4,  L 46: Personal preference for 'reverse' instead of 'oppose'. 
This now reads : “the enzymes that reverse the action of protein kinases, 
is relatively under-studied” 
•P 5,  L 51: 'cell line, HEK 293T [22] and' -> 'cell line HEK 293T [22], 
and' 
This now reads; “in the human embryonic kidney cell line HEK 293T [22], 
and in both leukemic T-cells” 
•P 7,  L 37: insert 'of' between 'weeks' and 'receipt' 
This now reads: “weeks of receipt” 
•P 8,  L 3:  Remove comma after vector. Perhaps add comma before 'and' to 
emphasize that pcDNA3.1 is the control 
This now reads: “Plasmids were pcDNA3.1-PP4c [23,27], and empty pcDNA3.1 
vector as control” 
•P 10, L 8:  I suspect this formula gives the percent unhealed wound 
area. Please verify. 
The formula has been changed.  
•P 13, L 33: 'to control for any' -> 'to control any' 
The requested change has been made. 
•P 15, Sub-title 3.3 and in subsequent occurrences: Ser116 numbering 
should not be a superscript. 
All Ser116 have been changed to Ser116.  
•P 15, L 6:  Please remove duplicated 'to be' 
The duplicated “to be” has been removed. 
•P 16, L 37: I suspect a word needs to be inserted after 'PEA15'. The 
oncogenic role is not simply its existence but rather its over-activity. 
Suggest adding the word 'over-expression'. 
This now reads “confirming an oncogenic role for PEA-15 over-expression 
in both oestrogen receptor-positive and TNBC cell lines” 
•P 16, L 39: The definition of TNBC should have been made upon first 
usage on P 12, L 54. 
TNBC  is now defined on P12, L54.  
•P 16, L 55: 'MCF-7' -> 'MCF7' like all the other occurrences in the 
manuscript. 
All instances of MCF-7 in the text have been changed to MCF7.  
 
•P 17, L 10 & 12: The same figure/subfigure is referred to in two 
different contexts.   Please amend. 
This has been amended and now reads: “Over-expression of PP4c in (-)siRNA 
transfected cells decreased the number of viable cells by more than 40% 
and enhanced the level of basal apoptosis but had no effect on the number 
of viable cells and the level of apoptosis in cells which had been 
previously transfected with PEA-15 siRNA (Figure 9C,D). 
 
•P 18: The first few lines appear to be very much a repetition of the 
last 4 lines on P 16 
We have changed these lines. This now reads : “ Increased in PP4c protein 
levels in both oestrogen receptor-positive and TNBC cells was associated 
with the consistent and significant decrease in both short and long term 
viability and stimulated apoptosis in the absence of extracellular 
stimuli.” 
•P 18, L 28: 'PP4c' here is superfluous. Please confirm / remove. 
The unnecessary PP4c has been removed.  
•P 18, L 45: The sentence starting 'PP4c also plays a role' feels like a 
repetition.  
 The sentence has been removed.  
•P 19, L 13: Please define what 'sensitizes' means. Does it make cells 
more sensitive  or less sensitive to cisplatin? 
This now reads: “inhibition of PP4c expression increased the sensitivity 
of breast and lung cancer cells to cisplatin treatment” 
•P 19, L 28: 'embryonic kidney human cells' -> 'human embryonic kidney 
cells' 
The change has been made.  
•P 20, L 52-60: Very long sentence, with intervening phrases that 
complicate the context. Suggest writing it as: 'Over-expression of PP4c 
(which correlated with increased apoptosis and reduced proliferation), 
caused a significant decrease in the phosphorylation level pf PEA15. 
Conversely, down-regulation of PP4c (which             stimulated 
proliferation and inhibited apoptosis), resulted in ...' 
 
This now reads: “Over-expression of PP4c (which correlated with increased 
apoptosis and reduced proliferation), caused a significant decrease in 
the phosphorylation level pf PEA15. Conversely, down-regulation of PP4c 
(which stimulated proliferation and inhibited apoptosis) prevented the 
de-phosphorylation of PEA15, leading to an increase in the content of its 
phosphorylated form at Ser116.” 
 
•P 22, L 17: The closing sentence ' These findings ...' is a repetition 
of a statement on the previous page. The authors need tom decide whether 
this is the correct place for this statement, or whether to down-play it 
in previous text. 
The statement in P21, L52-57 has been removed and placed on P 22, L 17, 
before the closing statement.   
 
Comments on 'Discussion' 
 
In response to the reviewer’s comments we have made the following changes 
to the discussion: 
•The interpretation of the results on P 19, starting on L 5, is a typical 
text for covering all bases. The authors true opinion is not coming 
through forcefully, as I think it ought to. This is a significant result 
and there should be strong direction from the authors as to what it 
means. It feels weak. 
To address the reviewer’s comments, we have inserted into the paragraph 
the following statement: “Our study reveals that PP4c endogenous level is 
of critical importance for the survival and growth of breast cancer 
cells”. 
We have also removed potential from the sentence : “point to a potential 
tumour suppressor function for this protein in breast cancer.” 
The paragraph now reads: 
“Our study reveals that PP4c endogenous level is of critical importance 
for the survival and growth of breast cancer cells. Modulation of the 
expression of the catalytic subunit of PP4 was shown to cause significant 
and specific effects on the survival and proliferation of breast cancer 
cells. Increased in PP4c protein levels in both oestrogen receptor-
positive and TNBC cells was associated with the consistent and 
significant decrease in both short and long term viability and stimulated 
apoptosis in the absence of extracellular stimuli. We have also shown 
that PP4c knockdown caused an increase in the rate of cell proliferation 
and migration in both cell types. Together, the data support an important 
role for PP4c in maintaining the delicate balance between cell survival 
and cell death in a range of breast cancer cell types and point to a 
tumour suppressor function for this protein in breast cancer.” 
•“The statement at the bottom of P 20 'Conversely, down-regulation of 
PP4c ... resulted in significant elevation ... of phosphorylated Ser116'. 
This last statement is not accurate. The increased phosphorylation is the 
result of depleted PP4c, but not caused by it.” 
Instead of “ down-regulation of PP4c …. resulted in significant elevation 
of phosphorylated Ser116'. We have changed the sentence   to “down-
regulation of ------- prevented the de-phosphorylation of PEA15, leading 
to an increase in the content of phosphorylated Ser116”. 
 
•The comment above is directly linked to the statement on P 21, L 30. 
PEA15 is not being switched from tumour suppressor to promoter. I think 
it is better described as a growth factor that needs to be carefully 
controlled, hence the existence of PP4c. 
We appreciate the comments relating to the tumour suppressor/ promotor 
activity of PEA-15. However, PEA15 has been described in the literature 
to display tumour suppressor or promoter activity dependent on its 
phosphorylation state (Please refer to Sulzmaier et al., 2012. 
Phosphorylation is the switch that turns PEA-15 from tumour suppressor to 
tumour promoter. Small GTPases. 2012; 3(3): 173–177). Therefore, we 
believe that it is justified to use this phrasing in relation to our work 
on the regulation of PEA15 activity by PP4. 
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Dear Professor Maurice  
In response to your Decision Letter, dated 2nd May 2016, I am submitting a further 
revised version of the manuscript: ‘The protein phosphatase 4 - PEA15 axis regulates the 
survival of breast cancer cells’, by H.N. Mohammed, M.R. Pickard, M. Mourtada-
Maarabouni, under consideration for publication as full length research article in your 
journal. 
 
We have addressed the Reviewers’ comments and accordingly have revised the 
manuscript. These revisions comprise changes to the original manuscript, all of which 
are supplied in the ‘Response to Reviewers’ document.   
 
We would like to take this opportunity to thank again the reviewers for their constructive 
comments, and we hope that our amended manuscript is now suitable for publication. 
 
Yours faithfully 
Dr M.Mourtada-Maarabouni 
 
 
 
Cover Letter
Reviewers’ comments 
Strengths and weaknesses  
We are pleased that the reviewer considers the work to be well accomplished and considers 
it to be worthy of publication.  Please find below our response to Reviewers’ Comments. 
 There is a tendency for repetition, which slightly distracted me (see comments below). 
However, this is due to the nature of the subject matter. If it can be reduced, that 
might be useful. I also felt that figures 1&2 can be merged, as well as Fig 3&4. A 
balance has to be struck between clarity and space, but the current layout is not too 
bad. 
Response:  
Two different breast cancer cell lines MCF7 and MDA-MB-231, were used in the present study.  The 
two cell lines were selected because they represent different breast cancer phenotypes. MCF-7 is a 
non-invasive cell line that is representative of estrogen-dependent breast cancer, whereas MDA-MB-
231 is an invasive, estrogen-independent cell line representative of triple negative breast cancer 
(TNBC).  On the one hand, MCF7 is the most widely studied of the currently available human breast 
cancer cell lines, hence the reason for its inclusion in the study here. On the other hand, there is 
currently a major need to identify novel molecular targets for therapy of TNBC (lacks oestrogen 
receptor, progesterone receptor and HER2 amplification), which can be highly malignant and often 
exhibits resistance to conventional chemotherapies [i.e. see Engebraaten et al. (2013)  Am J Pathol 
183:1064–1074]; consequently we believe that it is also important to include data from MDA-MB-
231 cells in the full paper. Because the two cell lines are representative of different breast cancer 
subtypes, we do not believe that it is justified to merge the various Figures. Indeed the reviewer 
does consider that ‘the current layout is not bad’. 
Minor amendments, typing errors and suggestions for improved syntax: 
We apologise for the typing errors – these have been corrected (Please see below). In response to 
the reviewer’s suggestions, the following changes have been made to the manuscript:  
 Page 1, Line 8: The activity of many of proteins 
This now reads: “the activity of many proteins” 
 P 1,  L 34-41: Long sentence. Suggest breaking it in L 34 after the word 'sequences' AND P 1,  L 
39: Missing word 'siRNAs related to ...'? 
This now reads: “ The breast cancer cell lines, MCF7 and MDA-MB-231, were transfected with 
expression vector encoding the catalytic subunit of protein phosphatase 4 (PP4c) or with PP4c 
siRNAs. Culture viability, apoptosis, cell migration and cell cycle were assessed.” 
 P 4,  L 1:  Comma between 'HERS' and HER2/Neu 
This now reads: “(HERs), HER2/Neu” 
Response to Reviewers
 P 4,  L 46: Personal preference for 'reverse' instead of 'oppose'. 
This now reads : “the enzymes that reverse the action of protein kinases, is relatively under-studied” 
 P 5,  L 51: 'cell line, HEK 293T [22] and' -> 'cell line HEK 293T [22], and' 
This now reads; “in the human embryonic kidney cell line HEK 293T [22], and in both leukemic T-
cells” 
 P 7,  L 37: insert 'of' between 'weeks' and 'receipt' 
This now reads: “weeks of receipt” 
 P 8,  L 3:  Remove comma after vector. Perhaps add comma before 'and' to emphasize that 
pcDNA3.1 is the control 
This now reads: “Plasmids were pcDNA3.1-PP4c [23,27], and empty pcDNA3.1 vector as control” 
 P 10, L 8:  I suspect this formula gives the percent unhealed wound area. Please verify. 
The formula has been replaced by : 
  
 P 13, L 33: 'to control for any' -> 'to control any' 
The requested change has been made. 
 P 15, Sub-title 3.3 and in subsequent occurrences: Ser116 numbering should not be a 
superscript. 
All Ser116 have been changed to Ser116.  
 P 15, L 6:  Please remove duplicated 'to be' 
The duplicated “to be” has been removed. 
 P 16, L 37: I suspect a word needs to be inserted after 'PEA15'. The oncogenic role is not simply 
its existence but rather its over-activity. Suggest adding the word 'over-expression'. 
This now reads “confirming an oncogenic role for PEA-15 over-expression in both oestrogen 
receptor-positive and TNBC cell lines” 
 P 16, L 39: The definition of TNBC should have been made upon first usage on P 12, L 54. 
TNBC  is now defined on P12, L54.  
 P 16, L 55: 'MCF-7' -> 'MCF7' like all the other occurrences in the manuscript. 
All instances of MCF-7 in the text have been changed to MCF7.  
 
 P 17, L 10 & 12: The same figure/subfigure is referred to in two different contexts.   Please 
amend. 
This has been amended and now reads: “Over-expression of PP4c in (-)siRNA transfected cells 
decreased the number of viable cells by more than 40% and enhanced the level of basal apoptosis 
but had no effect on the number of viable cells and the level of apoptosis in cells which had been 
previously transfected with PEA-15 siRNA (Figure 9C,D). 
 
 P 18: The first few lines appear to be very much a repetition of the last 4 lines on P 16 
We have changed these lines. This now reads : “ Increased in PP4c protein levels in both oestrogen 
receptor-positive and TNBC cells was associated with the consistent and significant decrease in both 
short and long term viability and stimulated apoptosis in the absence of extracellular stimuli.” 
 P 18, L 28: 'PP4c' here is superfluous. Please confirm / remove. 
The unnecessary PP4c has been removed.  
 P 18, L 45: The sentence starting 'PP4c also plays a role' feels like a repetition.  
            The sentence has been removed.  
 P 19, L 13: Please define what 'sensitizes' means. Does it make cells more sensitive  or less 
sensitive to cisplatin? 
This now reads: “inhibition of PP4c expression increased the sensitivity of breast and lung cancer 
cells to cisplatin treatment” 
 P 19, L 28: 'embryonic kidney human cells' -> 'human embryonic kidney cells' 
The change has been made.  
 P 20, L 52-60: Very long sentence, with intervening phrases that complicate the context. 
            Suggest writing it as: 'Over-expression of PP4c (which correlated with increased 
            apoptosis and reduced proliferation), caused a significant decrease in the 
            phosphorylation level pf PEA15. Conversely, down-regulation of PP4c (which 
            stimulated proliferation and inhibited apoptosis), resulted in ...' 
 
This now reads: “Over-expression of PP4c (which correlated with increased apoptosis and reduced 
proliferation), caused a significant decrease in the phosphorylation level pf PEA15. Conversely, 
down-regulation of PP4c (which stimulated proliferation and inhibited apoptosis) prevented 
the de-phosphorylation of PEA15, leading to an increase in the content of its 
phosphorylated form at Ser116.” 
 
 P 22, L 17: The closing sentence ' These findings ...' is a repetition of a statement on the 
previous page. The authors need tom decide whether this is the correct place for this 
statement, or whether to down-play it in previous text. 
The statement in P21, L52-57 has been removed and placed on P 22, L 17, before the closing 
statement.   
Comments on 'Discussion' 
In response to the reviewer’s comments we have made the following changes to the discussion: 
 The interpretation of the results on P 19, starting on L 5, is a typical text for covering all bases. 
The authors true opinion is not coming through forcefully, as I think it ought to. This is a 
significant result and there should be strong direction from the authors as to what it means. It 
feels weak. 
To address the reviewer’s comments, we have inserted into the paragraph the following statement: 
“Our study reveals that PP4c endogenous level is of critical importance for the survival and growth of 
breast cancer cells”. 
We have also removed potential from the sentence : “point to a potential tumour suppressor 
function for this protein in breast cancer.” 
The paragraph now reads: 
“Our study reveals that PP4c endogenous level is of critical importance for the survival and growth of 
breast cancer cells. Modulation of the expression of the catalytic subunit of PP4 was shown to cause 
significant and specific effects on the survival and proliferation of breast cancer cells. Increased in 
PP4c protein levels in both oestrogen receptor-positive and TNBC cells was associated with the 
consistent and significant decrease in both short and long term viability and stimulated apoptosis in 
the absence of extracellular stimuli. We have also shown that PP4c knockdown caused an increase in 
the rate of cell proliferation and migration in both cell types. Together, the data support an 
important role for PP4c in maintaining the delicate balance between cell survival and cell death in a 
range of breast cancer cell types and point to a tumour suppressor function for this protein in breast 
cancer.” 
 “The statement at the bottom of P 20 'Conversely, down-regulation of PP4c ... resulted in 
significant elevation ... of phosphorylated Ser116'. This last statement is not accurate. The 
increased phosphorylation is the result of depleted PP4c, but not caused by it.” 
Instead of “ down-regulation of PP4c …. resulted in significant elevation of phosphorylated Ser116'. 
We have changed the sentence   to “down-regulation of ------- prevented the de-phosphorylation of 
PEA15, leading to an increase in the content of phosphorylated Ser116”. 
 
 The comment above is directly linked to the statement on P 21, L 30. PEA15 is not being 
switched from tumour suppressor to promoter. I think it is better described as a growth factor 
that needs to be carefully controlled, hence the existence of PP4c. 
We appreciate the comments relating to the tumour suppressor/ promotor activity of PEA-15. 
However, PEA15 has been described in the literature to display tumour suppressor or promoter 
activity dependent on its phosphorylation state (Please refer to Sulzmaier et al., 2012. 
Phosphorylation is the switch that turns PEA-15 from tumour suppressor to tumour promoter. Small 
GTPases. 2012; 3(3): 173–177). Therefore, we believe that it is justified to use this phrasing in 
relation to our work on the regulation of PEA15 activity by PP4. 
Highlights 
 PP4c over-expression enhances apoptosis and decreases the short and long term survival of 
breast cancer cells. 
 Down-regulation of PP4c increases cell survival, migration and attenuates basal apoptosis in 
breast cancer cells. 
 PP4c regulates the phosphorylation of PEA15, and PEA15 itself regulates the survival of breast 
cancer cells.  
 The inhibitory effects of PP4c on cell survival are mediated through de-phosphorylation of 
PEA15.   
 The PP4-PEA15 signalling axis regulates the survival of breast cancer cells.   
*Highlights (for review)
Background 
 The control of breast cell survival is of critical importance for preventing breast 
cancer initiation and progression. The activity of many proteins which regulate cell 
survival is controlled by reversible phosphorylation, so that the relevant kinases and 
phosphatases play crucial roles in determining cell fate. Several protein kinases act 
as oncoproteins in breast cancer and changes in their activities contribute to the 
process of transformation. Through counteracting the activity of oncogenic kinases, 
the protein phosphatases are also likely to be important players in breast cancer 
development, but this class of molecules is relatively poorly understood. Here we 
have investigated the role of the serine/ threonine protein phosphatase 4 in the 
control of cell survival of breast cancer cells.  
Methods 
 The breast cancer cell lines, MCF7 and MDA-MB-231, were transfected with 
expression vectors encoding the catalytic subunit of protein phosphatase 4 (PP4c) or 
with PP4c siRNAs. Culture viability, apoptosis, cell migration and cell cycle were 
assessed. The involvement of phosphoprotein enriched in astrocytes 15 kD (PEA15) 
in PP4c action was investigated by immunoblotting approaches and by siRNA-
mediated silencing of PEA15.  
Results 
 In this study we showed that PP4c over-expression inhibited cell proliferation, 
enhanced spontaneous apoptosis and decreased the migratory and colony forming 
abilities of breast cancer cells. Moreover, PP4c down-regulation produced 
complementary effects. PP4c is demonstrated to regulate the phosphorylation of 
*Abstract
PEA15, and PEA15 itself regulates the apoptosis of breast cancer cells. The 
inhibitory effects of PP4c on breast cancer cell survival and growth were lost in 
PEA15 knockdown cells, confirming that PP4c action is mediated, at least in part, 
through the de-phosphorylation of apoptosis regulator PEA15. 
Conclusion 
 Our work shows that PP4 regulates breast cancer cell survival and identifies a novel 
PP4c-PEA15 signalling axis in the control of breast cancer cell survival. The 
dysfunction of this axis may be important in the development and progression of 
breast cancer.  
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Abstract 
Background 
 The control of breast cell survival is of critical importance for preventing breast 
cancer initiation and progression. The activity of many proteins which regulate cell 
survival is controlled by reversible phosphorylation, so that the relevant kinases and 
phosphatases play crucial roles in determining cell fate. Several protein kinases act 
as oncoproteins in breast cancer and changes in their activities contribute to the 
process of transformation. Through counteracting the activity of oncogenic kinases, 
the protein phosphatases are also likely to be important players in breast cancer 
development, but this class of molecules is relatively poorly understood. Here we 
have investigated the role of the serine/ threonine protein phosphatase 4 in the 
control of cell survival of breast cancer cells.  
Methods 
 The breast cancer cell lines, MCF7 and MDA-MB-231, were transfected with 
expression vectors encoding the catalytic subunit of protein phosphatase 4 (PP4c) or 
with PP4c siRNAs. Culture viability, apoptosis, cell migration and cell cycle were 
assessed. The involvement of phosphoprotein enriched in astrocytes 15 kD (PEA15) 
in PP4c action was investigated by immunoblotting approaches and by siRNA-
mediated silencing of PEA15.  
Results 
 In this study we showed that PP4c over-expression inhibited cell proliferation, 
enhanced spontaneous apoptosis and decreased the migratory and colony forming 
abilities of breast cancer cells. Moreover, PP4c down-regulation produced 
complementary effects. PP4c is demonstrated to regulate the phosphorylation of 
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PEA15, and PEA15 itself regulates the apoptosis of breast cancer cells. The 
inhibitory effects of PP4c on breast cancer cell survival and growth were lost in 
PEA15 knockdown cells, confirming that PP4c action is mediated, at least in part, 
through the de-phosphorylation of apoptosis regulator PEA15. 
Conclusion 
 Our work shows that PP4 regulates breast cancer cell survival and identifies a novel 
PP4c-PEA15 signalling axis in the control of breast cancer cell survival. The 
dysfunction of this axis may be important in the development and progression of 
breast cancer.  
 
Keywords 
PP4; PP4c; Breast cancer; PEA15, Cell survival.  
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1. Introduction  
Breast cancer is a highly complex and heterogeneous disease, and can be classified 
into different molecular subtypes according to the expression status of oestrogen 
receptor (ER), progesterone receptor (PR), and human epidermal growth factor 
receptors (HERs), HER2/Neu and HER1/EGFR [1,2]. Phosphorylation of these 
receptors on tyrosine (Tyr) residues constitutes a major regulatory mechanism of 
their activities. Aberrant activation of these receptors dysregulates multiple signalling 
cascades and plays a vital role in the initiation, development and progression of 
breast cancer, highlighting the importance of protein phosphorylation in the context 
of breast oncogenesis [3]. While the protein tyrosine kinase (PTK) families 
comprising the HERs and the non-receptor Src-family kinases (SFKs) have been 
directly implicated in the development and progression of breast cancer [3], their 
downstream signalling is mainly mediated via the activation of effector pathways that 
involve serine/threonine (Ser/Thr) kinases, including MAP kinase (MAPK), the 
phosphoinositide-3 kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) and 
the JAK/STAT signalling pathways [4]. The role of Ser/Thr kinases in breast cancer 
as crucial effectors in oncogenic PTK signalling has been well studied and multiple 
compounds that target their activity are being evaluated in clinical trials [5].  
In contrast, the role of protein phosphatases, the enzymes that reverse the action of 
protein kinases, is relatively under-studied. This is despite the tumour suppressor 
function of protein phosphatase 2A (PP2A), a major serine/threonine phosphatase, 
having been clearly demonstrated in breast, gastric and ovarian cancer cells [6]. 
Notably, the Ser/Thr phosphatase family contains a number of other subfamilies (i.e. 
PP1, PP4, PP5, PP6 and PP7), the tumour suppressive functions of which remain to 
be explored in detail in breast cells [7]. Nevertheless, evidence is emerging from 
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other cell types to indicate a crucial role for the PP4 subfamily in the control of cell 
survival, in particular [7]. PP4 (Protein phosphatase 4; PPP4; PPX) exists as a 
holoenzyme composed of a highly conserved catalytic subunit (PP4c) which 
interacts with different structural and regulatory subunits which control its activity, as 
well as its subcellular localisation [7]. A vast array of regulatory subunits have been 
described, including alpha 4/ immunoglobulin (CD79A) binding protein 1 (4/ IGBP1) 
which is the only subunit shared with PP2A [8-13]. 
Like PP2A, PP4 complexes are involved in multiple fundamental cellular processes, 
including nucleation, organelle assembly, regulation of microtubule growth, growth 
and maturation of the centrosome during cell division, cell migration, as well as 
spliceosomal assembly via interaction with the SMN complex [14,9].  At the 
molecular level, PP4 controls haematopoietic progenitor kinase 1 (HPK1), NFκB and 
histone deacetylase activities [15-17] and regulates JNK and the target of rapamycin 
(TOR) signalling pathways [18]. PP4 also regulates the dephosphorylation of H2AX, 
the replication protein A (RPA) [19,20] and KRAB-domain-associated protein 1 
(KAP-1) implicating it in regulation of the DNA damage response [21].  
Accumulating evidence has demonstrated that the catalytic subunit of PP4 (PP4c) 
plays important and complex roles in apoptosis and cell proliferation and 
consequently, in cancer. Over-expression of PP4c increases cell death and 
decreases cell proliferation in mouse thymoma cells [22], in the human embryonic 
kidney cell line HEK 293T [22], and in both leukemic T-cells and untransformed 
human peripheral T-cells [23]. In the latter cells, down-regulation of PP4c causes an 
increase in the rate of cell proliferation and confers resistance to a number of 
apoptotic stimuli [23]. On the other hand, a reduction in endogenous PP4c increases 
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the basal apoptotic rate of A549 and HeLa cells [24]. Such cell-specific effects of 
PP4c on cell survival could be related to the differential expression of the various 
regulatory subunits, resulting in the formation of PP4 complexes with distinct 
subcellular locations and molecular targets. Overall, these observations suggest that 
PP4c dysfunction may be important in the development and progression of cancer. 
The additional observation that PP4c expression is elevated in breast cancer [25,26], 
further highlights the need for further studies to characterise its role in breast cells. 
Proteomic analysis has shown that changes in PP4c expression in human embryonic 
kidney 293T cells affects the phosphorylation status of many proteins involved in 
apoptosis and cell proliferation, including the critical apoptosis regulator, 
phosphoprotein enriched in astrocytes 15 kD (PEA15) [27]. Further analysis has 
confirmed the interaction between PP4c and PEA15 and demonstrates that PP4c -
induced apoptosis in normal lymphocytes and T-leukemic cells is partly mediated 
through the direct or indirect dephosphorylation of PEA15 [23]. PEA15 is a member 
of the death effector domain (DED) protein family known to regulate cell proliferation, 
autophagy, and apoptosis [28,29]. It is implicated in the dysregulation of many 
signalling pathways involved in cancer progression and tumorigenesis and it has 
been described to act as both a tumour suppressor and a tumour promoter, 
dependent on its phosphorylation status [30-32]. The PEA15 gene is amplified in 
breast cancer, as well as in other cancers [33], and the unphosphorylated form of 
PEA15 is more potent than the phosphorylated form in suppressing tumorigenicity in 
breast cancer [34].  While several kinases have been reported to be involved in the 
phosphorylation of PEA15 including Akt, Ca2+/calmodulin-dependent protein kinase 
(CaMKII) and AMP-activated protein kinase (AMPK) [35,36], the dephosphorylation 
of PEA15 is much less understood.   
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
7 
 
In this study, we have investigated the role of PP4c in the control of survival of 
hormone-sensitive and triple-negative breast cancer cells. Firstly, we have 
investigated the hypothesis that PP4c regulates the survival and proliferation of 
breast cancer cells. Secondly, we have explored the interaction between PP4c and 
PEA15 and have specifically addressed the involvement of PEA15 in mediating the 
functional responses of breast cancer cells to PP4c. Together, these studies reveal 
the importance of PP4c expression levels in the control of survival of breast cancer 
cells and provide support for a tumour suppressor role for PP4c. Our findings also 
indicate that the critical role played by PP4c in maintaining the delicate balance 
between cell survival and cell death in breast cancer cells is mediated, at least partly, 
through the dephosphorylation of PEA15.  
2. Materials and methods 
2. 1. Cell culture 
The breast cancer cell lines MCF7 [37] and MDA-MB-231 [38] were generated from 
secondary stocks of cells which had been frozen down within two weeks of receipt 
from ATCC-LGC Promochem (Teddington, Middlesex, UK). Cells were cultured in R-
10 medium (RPMI-1640; Sigma Aldrich Company Ltd) supplemented with 2 mM L-
glutamine, 1 mM sodium pyruvate, 10 mM HEPES, 10% fetal bovine serum and 50 
µg/ml gentamicin at 37 °C in a humidified incubator with 5% CO2. Cell lines were 
replaced with freshly thawed stocks every 6 - 8 weeks. All experiments were carried 
out using cells in logarithmic growth phase.  
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2. 2. Plasmid DNA transfection 
Plasmids were pcDNA3.1-PP4c [23,27], and empty pcDNA3.1 vector as control. 
MCF7 breast cancer cells were transfected using TransIT-BrCa tranfection reagent 
(Mirus Bio LLC, Madison, USA) according to the manufacturer's instructions at a 
DNA: reagent ratio of 1:2. MDA-MB-231 cells were nucleofected (2 g plasmid per 2 
x 106 cells in 0.1 ml Ingenio solution (Mirus Bio LLC, Madison, USA)) using 
programme X-013. Following nucleofection, cells were plated in 3 ml R-10 medium in 
6-well plates. Efficiency of transfection was 70-80% for MCF7 and 80-85% for MDA-
MB-231.The level of expression of PP4c was monitored by western analysis [22,23]. 
 
2. 3. RNA interference 
MCF7 and MDA-MB-231 breast cancer cells were transfected with siRNAs to PP4c, 
using RNAiFect reagent (Qiagen, Crawley, UK) according to a standard protocol [39]. 
Three different PP4c specific siRNAs were employed, termed PP4s1 (targets exon 7; 
product code n105835), PP4s2 (targets exon 4; product code n105834) and PP4s8 
(targets exon 6, product code SI02658698); PP4s1 and PP4s2 were purchased from 
Life Technologies Ltd (Paisley, UK), whereas PP4s8 was purchased from Qiagen 
(Crawley, UK). Two different PEA15 specific siRNAs were used, termed PEA15s1 
and PEA15s2 (product codes/targeted exons are: n137203/ exon 4 and 
n43349/exon 2, respectively). Controls were transfected with negative control ((-
)siRNA; code AM4611, Life Technologies Ltd, Paisley, UK). Transfection efficiency 
(80–90% at 48 h) was determined in parallel transfections with Cy3-labelled (-)siRNA 
prepared using the SilencerTM siRNA labelling kit (Ambion; Cat# 1632). Monitoring 
of specific silencing of PP4c and PEA15 expression was carried out on samples 
collected at 72 h post-transfection by western blotting. 
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2.4. Determination of cell survival and apoptosis  
At 24 h post-transfection with plasmids or at 72 h post-transfection with siRNAs, cells 
were harvested by trypsinization then seeded (0.8 x105 cells for siRNA-transfected 
cells; 1.6 x 105 cells for plasmid-transfected cells) into 12-well plates. Cells were 
cultured for 24 and 48 h before being trypsinized to determine cell viability and 
apoptosis. Cell viability was determined by counting of nigrosin blue (0.1 %, w/v) 
stained samples using a haemocytometer and light microscopy. Cell viability was 
also determined using a commercial Cell Count and Viability Kit and a Muse flow 
cytometer (Merck Millipore, Darmstadt, Germany). Apoptosis was routinely 
determined by assessment of nuclear morphology by fluorescence microscopy after 
staining with acridine orange (25 µg/ml); cells containing condensed or fragmented 
chromatin were scored as apoptotic. Apoptosis was also measured by flow 
cytometry using a Muse annexin V and dead cell assay kit, according to the 
manufacturer’s protocol (Merck Millipore, Darmstadt, Germany). For clonogenic 
assays, cells were replated in culture medium supplemented with 10 % (v/v) cell-
conditioned medium in 6-well plates, cultured for 3 weeks, and then the number of 
colonies was counted after staining with crystal violet. Cell migration was assessed 
using the scratch wound healing assay. Cells were seeded in 24-well plates at a 
density of 1.6 × 104 cells/well in complete R-10 medium and cultured to confluence. 
The confluent cells were serum-starved for 24 hours, then cell monolayers were 
scratched using a 200 μl pipette tip to generate scratch wounds. Cells were washed 
twice with Opti-MEM (Invitrogen; # 51985-026) to remove cell debris and serum-
containing media was added to each well. The initial wound area was measured in 
four places using a calibrated eyepiece graticule to document the pre-migration area 
of the cell-free detection zone.  The distance across each wound was then measured 
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in four places every 18 hour or until wounds were completely closed. Cells were 
incubated at 37 °C, 5% CO2 at all times. Cell migration is presented as percent 
wound closure and was calculated using the following equation:  
 
 
 
 
2. 5. Cell cycle analysis 
Cell cycle analysis was assessed by flow cytometry following nuclear propidium 
iodide staining using the Muse cell cycle kit (Merck Millipore, Darmstadt, Germany). 
At 24 h post-transfection with plasmids or at 72 h post-transfection with siRNAs, cells 
were harvested by trypsinization and were plated in fresh medium at 5 × 105 
cells/well in 4 ml medium in 6-well plates.  Following incubation for 24 h, cells (~106) 
were suspended in 200 µl phosphate buffered saline (PBS), and fixed in 1 ml ice-
cold 70% ethanol/30% PBS. Cells were incubated at -20 °C for at least three hours. 
Cells were then re-suspended in 200 µl of Muse™ Cell Cycle Reagent and incubated 
for 30 minutes in the dark before data was acquired using the Muse Cell analyser. 
2. 6. Western blot analysis 
Cells (106) were washed twice in PBS and lysed in 50 μl lysis buffer (50 mM Tris–
HCl, pH 7.5; 150 mM NaCl, 1% Nonidet P40, 1 mM EDTA, 1 μM Pepstatin, 10 μg/ml 
Leupeptin, 1 mM PM Phenylmethanesulfonyl fluoride (PMSF))  on ice for 30 min. 
Samples were then centrifuged (10,000 g, 10 min) to remove debris. The protein 
content of the supernatant was quantified using the Coomassie Plus™ protein assay 
reagent (PIERCE; Waltham, MA, USA). Protein samples (50 μg) were boiled for 10 
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min in sample buffer (10% glycerol, 0.7M β-mercaptoethanol, 3% SDS, 62 mM Tris–
HCl, pH 6.8), electrophoresed (12% SDS-polyacrylamide gels), then 
electrotransferred onto a polyvinylidenedifluoride membrane (Biorad, Hertfordshire, 
UK). The blots were probed with either  anti-PP4c antibody (PPX/PP4 (C-18); 1:1000 
dilution; Santa Cruz Biotechnology, Heidelberg , Germany # Sc6118), anti-PEA15 
antibody (1:1000 dilution, Santa Cruz # Sc28255), or phosphospecific anti-PEA15 
specific for Ser116 (P-PEA15, dilution 1:500; # 44-836G; Biosource) followed by the 
appropriate horseradish peroxidase-conjugated secondary antibodies. Blots were 
stripped using Restore(TM) Plus Western Blot Stripping Buffer Kit (Pierce; # 
10016433) and reprobed with anti-β-actin antibody (dilution 1:5000; Sigma, # 
A5441). The secondary antibodies used were anti-goat IgG (diluted 1:10.000; Sigma, 
# A5420), anti-mouse immunoglobulin (diluted 1:800; Dako, # P0447) and anti-rabbit 
IgG (diluted 1:10000; Sigma, # A0545). Protein bands were visualised by enhanced 
chemiluminescence (ECL) according to the manufacturer's instructions (Amersham 
Pharmacia Biotech, ,Little Chalfont, Buckinghamshire, UK) signals were captured 
utilizing the Odyssey® Imager (Li-Cor, Lincoln, Nebraska USA) and densitometric 
analysis carried out using the associated Image Pro analysis software (version 3.1).  
2. 7. Statistical analyses 
Data are presented as the mean ± SEM; the number of observations (n) refers to 
different transfected samples (each from separate cultures) or separate cultures. 
Data analysis was either by an unpaired Student’s t test or by one-way analysis of 
variance with Bonferroni’s multiple comparison test (MCT). Statistical analyses were 
performed using GraphPad Prism 6; a p-value of <0.05 was considered statistically 
significant. 
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3. Results  
3.1. Transient expression of PP4c enhances apoptosis and decreases the survival of 
breast cancer cells 
To examine the effects of increased PP4c expression on breast cancer cell survival, 
MCF7 cells were transiently transfected with a pcDNA3.1 expression plasmid 
containing full length cDNA encoding PP4c. The influence of PP4c over-expression 
on cell survival and apoptosis was then examined under basal conditions. Transient 
transfection resulted in an approximate doubling in PP4c protein level at 24 h post 
transfection (Fig. 1A). This had significant effects on cell survival and basal 
apoptosis. Compared to cultures of untransfected cells and cells transfected with 
empty vector, the number of both total and viable cells in cultures over-expressing 
PP4c was considerably decreased at 48 h, as assessed by vital dye staining and 
flow cytometry (Fig. 1B and S1A). Cells over-expressing PP4c also showed a 15–
20% increase in apoptotic cells (Fig. 1C and S1B). In order to determine whether the 
growth suppression produced by PP4c was due to apoptosis, to cell cycle arrest, or 
to both, a cell cycle analysis was performed using propidium iodide staining and flow 
cytometry. The results revealed a significant increase in the proportion of cells in the 
sub-G0 phase in PP4c over-expressing cultures, suggesting an increase in the 
apoptosis rate, and a consistently lower percentage of cells in G1 and S phases (Fig.  
1D). In the longer term, these various effects resulted in a significant decrease in the 
clonogenic activity of MCF7 cells (Fig. 1E). 
To confirm these findings, the triple-negative breast cancer (TNBC) cell line, MDA-
MB-231, was transfected with the plasmid encoding PP4c. This also produced an 
approximate doubling of cellular PP4c protein levels (Fig. 2A) and caused a 
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significant reduction in total and viable cell number (Fig. 2B and S2A).  This was also 
associated with a doubling of basal apoptosis (Fig. 2C and  S2B). Cell cycle analysis 
confirmed an increase in the proportion of cells in the sub-G0 fraction after 
transfection with pcDNA3.1-PP4c, whereas the proportions of cells in G1, S and 
G2/M phases were decreased (Fig. 2D).  Over-expression of PP4c in MDA-MB-231 
also caused a significant reduction in the clonogenic activity of these cells (Fig.  2E). 
Thus, PP4c causes growth arrest, induces apoptosis and decreases long term 
survival in both triple-negative MDA-MB-231 cells and oestrogen receptor-positive 
MCF7 cells. 
3. 2. PP4c silencing increases cell survival, migration and attenuates basal apoptosis 
in breast cancer cells 
In order to investigate PP4c function further in MCF7 and MDA-MB-231 cells, siRNA-
mediated silencing of PP4c expression was conducted using two different PP4c-
specific siRNAs per cell line, which target different exons, in order to control any ‘off-
target’ effects. This complementary strategy of independent over-expression and 
gene silencing approaches is particularly important to exclude possible artefacts. 
The efficiency of PP4c knockdown was determined by immunoblotting 72 h post-
transfection and the influence of PP4c silencing on long- and short-term cell survival 
and apoptosis was again examined under basal conditions.  
In MCF7 cells, the two PP4c-targeted siRNAs each reduced PP4c protein levels by 
70 - 80% (Fig. 3A). Both siRNAs increased the numbers of total and viable cells (Fig.  
3B and S3A) and decreased the level of basal apoptosis (Fig. 3C and S3B). Cell 
cycle analysis revealed that PP4c silencing decreased the proportion of cells in sub-
G0 and increased the proportions of cells in S and G2/M phases (Fig. 3D). The 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
14 
 
clonogenic activity of MCF7 cells was also increased in the cells transfected with 
PP4c specific siRNAs (Fig. 3E). 
siRNA-mediated silencing of PP4c expression in MDA-MB-231 produced an 80 - 
85% decrease in endogenous PP4c protein levels (Fig. 4A). As in MCF7 cells, this 
was associated with an increase in the number of total and viable cells (Fig. 4B and 
S4A) and a decrease in spontaneous apoptosis (Fig. 4C and S4B). Cell cycle 
analysis confirmed that PP4c silencing produced a substantial reduction in the 
proportion of cells in the sub-G0 fraction (Fig. 4D). The proportion of cells in G1 was 
also consistently lower compared to the negative control siRNA, whereas the 
proportion of cells in S and G2/M phases was consistently higher, suggesting that 
PP4c down-regulation may accelerate G1 progression (Fig.  4D). PP4c silencing also 
significantly increased the long term survival of MDA-MB-231, as shown by an 
increase in the number of colonies formed (Fig.  4E).  
The effect of PP4c silencing on cell migration was also assessed using an in-vitro 
scratch assay. RNA mediated silencing of PP4c promoted cell migration in both 
MCF7 and MDA-MB-231 cells. As shown in Fig. 5A, down-regulation of PP4c was 
found to increase MCF7 cell migration by up to 30% at 36, 54 and 72 h  compared 
with (-)siRNA and mock transfected cells.  Consistent with these observations, PP4c 
knockdown in MDA-MB-231 cells showed a significant increase in cell migration 
ability by 30% at 18 h and by 20% at 36 and 54 h (Fig. 5B). Overall, the data indicate 
that PP4c down-regulation enhances breast cancer cell proliferation and migration, 
with implications for breast cancer progression and metastasis.  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
15 
 
3. 3. PP4c down-regulation leads to an increase in the PEA15 Ser116 
phosphorylation  
PEA15 is one of the proteins reported to be regulated, directly or indirectly, through 
dephosphorylation by PP4c [30,35]. Previous studies have shown that over-
expression of PP4c correlates with dephosphorylation of PEA15 on Ser116, while 
PP4c silencing results in an increase in the level of phosphorylated Ser116 [23,27]. 
In order to investigate whether PP4c regulates the phosphorylation level of PEA15 in 
breast cancer cells, the status of PEA15 phosphorylation was measured in the cells 
transfected with PP4c siRNAs and pcDNA3.1-PP4c using an antibody that 
specifically recognises the phosphorylated form of PEA15 on Ser116. Western blot 
analysis on proteins extracted from MCF7 and MDA-MB-231 PP4c knockdown cells 
revealed that PEA15 phosphorylation state significantly increased when PP4c 
expression was suppressed. PP4c down-regulation caused up to 1.5 - 2-fold 
increase in the phosphorylated form of PEA15 on Ser116 in MCF7 (Fig. 6A) and in 
MDA-MB-231 cells (Fig.  6B). Western blot analysis on proteins extracted from 
MCF7 cells over-expressing PP4c revealed that over-expression of PP4c caused a 
corresponding decrease in the phosphorylation state of PEA15 (Fig. 6C), providing 
further evidence to support the involvement of PP4c in regulating the 
phosphorylation status of PEA15.  
 
3. 4. The effects of PP4c on cell survival and apoptosis are mediated at least partly 
by PEA15  
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The control of apoptosis and cell proliferation by PP4c in leukemic and primary 
human T-cells was demonstrated to be mediated at least partly through the 
dephosphylation of PEA15 on Ser116 [23,27]. Further experiments were carried out 
in order to investigate whether PEA15 plays a major role in mediating the pro-
apoptotic and growth inhibitory effects of PP4c in breast cancer cells. Two PEA15-
specific siRNAs were used to down-regulate PEA15 before studying the effects of 
modulation of PP4c expression on cell viability. Down-regulation of PEA15 in MCF7 
cells was assessed at 48 h post-transfection which showed that both PEA15 siRNAs 
were effective in causing a decrease in PEA15 protein levels by 60 - 75% (Fig.  7A). 
In agreement with a previous study [36], down-regulation of PEA15 resulted in 
significant decreases in the number of viable cells (Fig. 7B) and cell viability (Fig.  
7C), and a significant increase in basal apoptosis (Fig. 7D). Consistent with these 
observations, silencing of PEA15 gene expression in MDA-MB-231 cells also 
resulted in a decrease in PEA15 protein levels (Fig. 8A) and this was accompanied 
by reductions in the viable cell number (Fig. 8B) and cell viability (Fig. 8C), and an 
increase in basal apoptosis (Fig. 8D), confirming an oncogenic role for PEA15 over-
expression in both oestrogen receptor-positive and TNBC cell lines.  
To investigate a potential role for PEA15 in PP4c action, control cells (transfected 
with (-) siRNA) and cells transfected with PEA15 siRNAs were transiently transfected 
with pcDNA3.1-PP4c or pcDNA3.1 (transfection efficiency 70 – 80%). Over-
expression of PP4c was assessed by western blotting which showed a two-fold 
increase in the level of PP4c in the cells transfected with PP4c expression vector 
(data not shown). In MCF7 cells transfected with (-) siRNA, over-expression of PP4c 
caused the expected reduction in viable cell number (Fig. 9A) and the expected 
increase in basal apoptosis (Fig. 9B). In contrast, over-expression of PP4c in cells 
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which had been previously transfected with PEA15 siRNA had no effects on the 
viable cell number and apoptosis level (Fig. 9A, B). These findings were confirmed in 
the TNBC MDA-MB-231 cells. Over-expression of PP4c in (-)siRNA transfected cells 
decreased the number of viable cells by more than 40% and enhanced the level of 
basal apoptosis but had no effect on the number of viable cells and the level of 
apoptosis (Fig. 9C,D). 
4. Discussion 
Reversible protein phosphorylation, controlled by the opposing action of protein 
kinases and phosphatases, regulates many cellular processes. Disturbance to the 
well balanced function of kinases and phosphatases contributes to the development 
and progression of various cancers including breast cancer [5]. Many kinases are 
now characterised to be oncogenic and changes in their activities have been linked 
to the pathogenesis and progression of breast cancer. However, the roles played by 
the phosphatases are much less clear and less well studied, although logically, they 
must be important through their ability to counteract the activities of the kinases [5]. 
Indeed, phosphatases such as PP2A [41,42], phosphatase and tensin homologue 
deleted on chromosome 10 (PTEN) and Src homology 2 (SH2)-containing inositol 5-
phosphatase (SHIP) are recognised as potential therapeutic targets due to their 
tumour suppressor activities [43,23]. Here we demonstrate, for the first time, that the 
serine/threonine phosphatase PP4 regulates the survival, proliferation and migration 
of oestrogen receptor-positive and TNBC breast cancer cells. We further 
demonstrate that these effects are mediated in part by modulation of the 
phosphorylation state of PEA15, pointing to the existence of a PP4c-PEA15 axis that 
controls breast cancer cell fate. 
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Our study reveals that PP4c endogenous level is of critical importance for the 
survival and growth of breast cancer cells. Modulation of the expression of the 
catalytic subunit of PP4 was shown to cause significant and specific effects on the 
survival and proliferation of breast cancer cells. Increased in PP4c protein levels in 
both oestrogen receptor-positive and TNBC cells was associated with the consistent 
and significant decrease in both short and long term viability and stimulated 
apoptosis in the absence of extracellular stimuli. We have also shown that PP4c 
knockdown caused an increase in the rate of cell proliferation and migration in both 
cell types. Together, the data support an important role for PP4c in maintaining the 
delicate balance between cell survival and cell death in a range of breast cancer cell 
types and point to a tumour suppressor function for this protein in breast cancer.  
 Indeed PP4c has been reported to negatively regulate the survival of other cell 
types, including both leukemic T-cells and untransformed human peripheral blood T-
cells [23], in keeping with our findings here.  Studies of a wide range of cell types 
other than breast epithelial cells have revealed that PP4 regulates an increasing 
number of cellular functions. The pleiotropic effects of PP4c have been related to the 
existence of different PP4 complexes that have different compositions as a result of 
the interaction of PP4c with different regulatory subunits [7,16]. The enzyme is 
involved in the regulation of microtubule growth and organization at the centrosomes 
[9], centrosome maturation in mitosis and meiosis and DNA damage response [8, 
44]. Recent evidence suggested that PP4c controls neural progenitor cell 
proliferation and differentiation in the mouse neocortex by regulating the 
phosphorylation status of Nuclear distribution protein nudE-like1 (Ndel1) [34]. PP4c 
interacts with and down-regulates insulin receptor substrate 4 (IRS4) following 
tumour necrosis factor-alpha (TNF-α) stimulation leading to the inhibition of the anti-
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apoptotic function of IRS4 [45]. Such evidence is entirely consistent with the findings 
form the present studies and suggest potential downstream mechanisms underlying 
regulation of cell survival by PP4c in a cell context-dependent manner.  
 On the other hand, the exact role of PP4c in relation to cancer is not clear, with 
some studies suggesting a tumour suppressor role, while others support an 
oncogenic role. For example, PP4c levels are increased in human breast and lung 
tumours, and inhibition of PP4c expression increased the sensitivity of breast and 
lung cancer cells to cisplatin treatment, suggestive of an oncogenic function [25]. 
PP4c is also over-expressed in pancreatic ductal adenocarcinoma (PDAC) and is 
associated with a poor prognosis [26]. Also PP4c has been reported to be expressed 
constitutively in prostate cancer cell lines (PC-3 and LNCaP) where it acts as a 
positive regulator of the MAP kinase JNK-1 [18]. Other studies have however shown 
that PP4c over-expression in 293T human embryonic kidney cells, T-leukemic cells 
and primary lymphocytes causes an increase in apoptosis, an inhibition of cell 
proliferation by inducing cell cycle arrest in G1 and a significant decrease in the 
mutation rate, and conversely, that decreased PP4c protein expression increases 
the rate of cell proliferation and protects the cells against apoptosis induction by a 
range of stimuli [22-27]. These and present findings together support a tumour 
suppressor role for PP4c. To resolve these conflicting views, further information is 
required about the functional activity of PP4c in breast and other cancers, especially 
since this is dependent on the expression of regulatory subunits. For example, the 
regulatory subunit, PP4R1, is down-regulated in a subset of malignant T 
lymphocytes derived from patients with a severe form of cutaneous T cell lymphoma, 
resulting in inactive PP4c. This in turn results in constitutive IKK/NF-kB signalling, 
suggesting that PP4R1-PP4c complex serves as a negative regulator of IKK activity 
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[16]. It is therefore important to elucidate the functional status of the catalytic 
subunits in breast cancer and further investigate the precise roles of other individual 
regulatory subunits and their potential functions during transformation. The possibility 
of the existence of an endogenous inhibitor should also be investigated, since an 
endogenous inhibitor of the closely related phosphatase PP2A, has been identified in 
cells undergoing blast crisis in chronic myeloid leukaemia [46].  
A key finding in these studies was that PP4c influenced the phosphorylation status of 
PEA15, especially since PEA15 is itself implicated in the regulation of cell 
proliferation and apoptosis [27]. Proteomic analysis has shown that changes in PP4 
expression levels affect the phosphorylation status of many proteins involved in 
apoptosis and cell proliferation, including PEA15 [27]. PEA15 is a multi-functional 
protein that has been implicated in the regulation of major intracellular processes 
including proliferation and apoptosis, and its function is tightly regulated by its 
phosphorylation at two serine residues, Ser104 and Ser116 [27]. Both CaMKII and 
AKT phosphorylate PEA15 at Ser116 [47-49] and, more recently, AMPK was 
reported to act as an upstream kinase of PEA15 in both normal and cancerous 
breast epithelial cells [36]. Phosphatases play an equally important role as kinases in 
regulating the phosphorylation state of PEA15. In this regard, a loss of PTEN 
function commonly seen in tumour cells is associated with an increased PEA15 
phosphorylation at Ser116 and an inhibition of Fas-mediated apoptosis [50]. 
However, evidence suggests that PTEN does not dephosphorylate PEA15 directly, 
but it modulates its phosphorylation level by controlling AKT activity [50]. In this 
study, we show that PP4c also regulates the phosphorylation of PEA15 at Ser116. 
Over-expression of PP4c (which correlated with increased apoptosis and reduced 
proliferation), caused a significant decrease in the phosphorylation level of PEA15. 
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Conversely, down-regulation of PP4c (which stimulated proliferation and inhibited 
apoptosis) prevented the de-phosphorylation of PEA15, leading to an increase in the 
content of its phosphorylated form at Ser116.  Consistent with these observations, 
others have reported that the non-phosphorylated form of PEA15 binds to the 
extracellular signal-regulated kinase 1/2 (ERK1/2), preventing its nuclear 
accumulation, leading to the inhibition of cell proliferation [30,31]. On the other hand, 
phosphorylation of PEA15 on Ser116 promotes its binding to Fas-associated death 
domain protein (FADD) via its DED domain, preventing FADD-mediated activation of 
caspases and the formation of the death inducing signalling complex (DISC), leading 
to the inhibition of the extrinsic apoptotic pathway [30,33,47]. 
Down-regulation of PEA15 expression was found to inhibit cell growth and to reduce 
viable cell number and viability, confirming an anti-apoptotic role for PEA15 in breast 
cancer cells.  Crucially, PP4c had no effect on apoptosis in cells with prior 
knockdown of PEA15 expression, suggesting that the induction of apoptosis by PP4c 
is mainly mediated through PEA15. Consequently, PP4c may be involved in 
mediating the switch of PEA15 from a tumour promoter to a tumour suppressor. As 
discussed above, recent studies have shown that AMPK directly phosphorylates 
PEA15 at Ser116, thereby converting it to a tumour promoter, resulting in increased 
survival and anchorage-independent growth of normal and breast cancer cells, both 
in vivo and in vitro [36]. Thus, PP4c which dephosphorylates PEA15, may counteract 
the effects of AMPK by switching the activity of PEA15 from a tumour promoter to a 
tumour suppressor. In this regard, the balance in the activities of AMPK and PP4c 
are likely to be crucial in determining the phosphorylation status of PEA15 and 
consequently, the development and progression of breast cancer.  
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In summary, oncogenic activation of protein kinases is a common feature in breast 
cancer, and many anticancer drugs that target these enzymes are now available. 
Protein phosphorylation is also controlled by protein phosphatases which, compared 
to kinases, are relatively under-studied. Our studies indicate that PP4c plays a 
critical role in the delicate balance of cell survival and cell death in breast cancer 
cells and that these effects are mediated mainly through the dephosphorylation of 
PEA15, switching the activity of this molecule from a tumour- promoter to a tumour- 
suppressor. Our study also highlights the high potential therapeutic value of targeting 
PEA15 and its interactions, which may provide a wider window of opportunities to 
treat breast cancer. These findings suggest that modulating the levels and activities 
of PP4c and/or PEA15 may prove important novel strategies for the treatment of 
breast cancer.  
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Fig. 1. 
PP4c over-expression inhibits cell growth, colony-forming ability, and 
increases apoptosis of MCF7 cells. MCF7 cells were transfected with 
pcDNA3.1-PP4c or empty pcDNA3.1. (A) Cellular levels of PP4c are 
increased in the cells transfected with the PP4c expression construct as 
determined by western blotting analysis; β-actin as a loading control. 
Representative immunoblots are presented to the right of the bar chart. (B) 
Total and viable cell counts, as determined by flow cytometry, are reduced in 
cells at 48 h post-transfection with PP4c. (C) The proportion of apoptotic cells, 
determined by annexin V staining and flow cytometry, is increased in PP4c 
transfected cells. (D) Cell cycle analysis revealed that PP4c over-expression 
reduces the proportions of cells in G1- and S-phases, while increasing the 
sub-G0 cell count. (E) Clonogenic assay demonstrates that long-term survival 
of MCF7 cells is compromised after transfection with the PP4c construct; an 
example image of a clonogenic assay plate after crystal violet staining is to 
the right of the bar chart. The bar graphs represent means ± SEM from four 
independent experiments. *P < 0.05 versus cells transfected with pcDNA3.1 
alone (Student’s t test). 
 
Fig. 2.  
PP4c induces apoptosis and inhibits short and long term survival in triple-
negative MDA-MB-231 cells. MDA-MB-231 cells were transfected with 
pcDNA3.1-PP4c or empty vector pcDNA3.1. (A) PP4c protein levels are 
increased in cells transfected with the PP4c expression construct, as 
determined at 24 h post transfection by western blotting analysis; β-actin as a 
loading control. Representative immunoblots are presented to the right of the 
bar chart. (B) Total and viable cell counts, determined by flow cytometry, are 
decreased in cells transfected with PP4c. (C) The percentage of apoptotic 
cells, as determined by annexin V staining and flow cytometry, is increased at 
48 h post transfection with PP4c. (D) PP4c over-expression disturbs the cell 
cycle profile of MDA-MB-231 cells, causes an increase in cell count in the 
sub-G0 phase and a concomitant decrease in proliferating cells in G1, S and 
G2/M phases. (E) Clonogenic activity of MDA-MB-231 is significantly 
decreased after transfection with PP4c construct. An example image of 
clonogenic assay plates after crystal violet staining is to the right of the bar 
chart. The bar graphs represent means ± SEM from four independent 
experiments. *P < 0.05 versus cells transfected with pcDNA3.1 alone 
(Student’s t test). 
 
Fig.  3. 
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 PP4c-specific siRNAs inhibit basal apoptosis and increase the short and long 
term survival of MCF7 cells. MCF7 cells were transfected with control (−) 
siRNA or with PP4c-specific siRNA. Cells were harvested at 72 h post-
transfection, and re-plated for assessment of cell survival after a further 48 h. 
(A) Expression of PP4c protein levels was determined by western blotting 72 
h after transfection and equivalent loading was demonstrated using anti- -
actin antibody. Representative immunoblots are presented. (B) Down-
regulation of PP4c is associated with an increase in total and viable cell 
numbers, as determined by flow cytometry. (C) The level of basal apoptosis, 
measured by annexin V staining and flow cytometry, is decreased in cells 
transfected with PP4c siRNAs. (D) Cell cycle analysis revealed that PP4c 
down-regulation affects the cell cycle profile of MCF7 cells, decreases the 
percentage of cells in sub-G0 and increases the percentage of cells in S and 
G2/M populations. (E) Colony forming ability is enhanced in the cells 
transfected with PP4c siRNAs. An example image of clonogenic assay plates 
is shown on the right. The bar graphs represent means ± SEM from four 
independent experiments. *P < 0.05 versus cells transfected with (-)siRNA 
control (one-way ANOVA and Bonferrroni's MCT). 
 
Fig. 4.  
siRNA-mediated PP4c knockdown reduces basal apoptosis and enhances the 
survival of MDA-MB-231 cells. MDA-MB-231 cells were transfected with 
PP4c-specific siRNAs or negative control (-) siRNA.  Cells were harvested at 
72 h post-transfection for protein expression analysis and re-plated for 
assessment of cell survival after a further 48 h. (A) The protein level of PP4c 
was determined by western blotting and anti- -actin was used as a loading 
control. Representative immunoblots are presented. (B) Down-regulation of 
PP4c increases total and viable cell counts, as assessed by flow cytometry. 
(C) PP4c knockdown protects against basal apoptosis, measured by annexin 
V staining and flow cytometry. (D) Cell cycle analysis revealed that PP4c 
down-regulation affects the cell cycle profile of MDA-MB-231 cells, reduces 
the proportion of cells in sub-G0 and G1 and increases the proportion of cells 
in S and G2/M phases. (E) PP4c down-regulation increases long term 
survival; a representative clonogenic assay plate is shown on the right. The 
bar graphs represent means ± SEM from four independent experiments. 
*P<0.05 versus cells transfected with (-) siRNA control (one-way ANOVA and 
Bonferrroni's MCT). 
 
Fig. 5. 
PP4c down-regulation enhances the migratory ability of breast cancer cell 
lines. MCF7 and MDA-MB-231 cells were transfected with PP4c-specific 
siRNAs or negative control (-) siRNA. Cells were harvested at 72 h post-
transfection for cell migration analysis using the scratch wound healing assay. 
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Cell migration is presented as percent wound closure (A) PP4c silencing 
increases MCF7 cell migration. (B) PP4c silencing also increases MDA-MB-
231 cell migration. Example images of cells at 36 h post-wounding are shown 
on the right of the bar chart. Data are presented as means ± SEM from four 
independent experiments. *P<0.05 versus cells transfected with (-) siRNA 
control (one-way ANOVA and Bonferrroni's MCT). 
 
Fig. 6.  
PP4c regulates the phosphorylation state of PEA15 at Ser116.  (A) MCF7 and 
(B) MDA-MB-231 cells were transfected with PP4c-specific siRNAs or 
negative control  (-) siRNA. Cells were harvested at 72 h post- transfection 
and the effects of PP4c down-regulation on the phosphorylation of PEA15 
was assessed by western Blot analysis using phospho-specific anti-PEA15.  
Each lane contains 50 μg of whole-cell lysate.  (A) PP4c down-regulation in 
MCF7 cells is associated with an increase in the phosphorylation of PEA15 on 
Ser116. (B) Transfection of MDA-MB-231 with PP4c-specific siRNAs causes 
a significant increase in the phosphorylation of PEA15 on Ser116. (C) MCF 
cells were transfected with pcDNA3.1-PP4c or empty pcDNA3.1. The effects 
of PP4c over-expression on the phosphorylation of PEA15 was assessed 
after 48h. PP4c up-regulation in MCF7 cells results in a decrease in the 
phosphorylation of PEA15 on Ser116. Quantification of phosphorylated 
PEA15 (P-PEA15) was determined by densitometry relative to PEA15 protein 
and results are expressed as relative percent change compared to control 
(mock transfected cells). Each bar represents the mean ± SEM from four 
independent experiments. Representative immunoblots are shown. *P<0.05 
versus cells transfected with (-) siRNA control (one-way ANOVA and 
Bonferrroni's MCT). 
 
Fig. 7.  
 PEA15 down-regulation is associated with an increase in apoptosis and a 
reduction in the viability of MCF7 cells. MCF7 cells were transfected with 
PEA15-specific siRNAs or negative control (-)siRNA. At 72 h post 
transfection, cells were harvested to assess PEA15 protein levels and re-
plated for assessment of cell survival after a further 48 h. (A) Expression of 
PEA15 protein was determined by western blotting and equivalent loading 
was demonstrated using anti-
are presented. (B) siRNA- mediated silencing of PEA15 reduces viable cell 
number, as assessed by flow cytometry. (C) siRNA- mediated silencing of 
PEA15 decreases short term viability. (D) Down-regulation of PEA15 is 
associated with an increase in the proportion of apoptotic cells, measured by 
annexin V staining and flow cytometry. Results are represented as means ± 
SEM from four independent experiments. *P < 0.05 compared with (−)siRNA 
transfected cells (one-way ANOVA and Bonferrroni's MCT).  
 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
30 
 
Fig. 8. 
 PEA15 specific siRNAs enhanced basal apoptosis and inhibited short term 
survival of the triple negative MDA-MB-231 breast cancer cells. MDA-MB-231 
cells were transfected with PEA15-specific siRNAs or negative control (-) 
siRNA. At 72 h post transfection, cells were harvested to assess PEA15 
protein levels and re-plated for assessment of cell survival after a further 48 h. 
(A) Expression of PEA15 protein was determined by western blotting and 
equivalent loading was demonstrated using anti- -actin antibody. 
Representative immunoblots are presented. (B) Transfection of MDA-MB-231 
with PEA15 specific siRNAs is associated with a decrease in total and viable 
cell count. (C) PEA15 knockdown causes loss of short term viability, as 
determined by flow cytometry. (D) PEA15 knockdown leads to an increase in 
the proportion of apoptotic cells, as measured by annexin V staining and flow 
cytometry. Data are presented as the means ± SEM from four independent 
experiments. *P < 0.05 compared with (−)siRNA transfected cells (one-way 
ANOVA and Bonferrroni's MCT). 
 
 
Fig. 9.  
Down-regulation of PEA15 abolishes PP4c-mediated loss of cell viability in 
MCF7 ad MDA-MB-231 breast cancer cell lines. Cells were transfected with 
PEA15-specific siRNAs to down-regulate PEA15, control cells were 
transfected with (-)siRNA. At 48 h post transfection, PEA15 down-regulation 
was assessed by western blotting (Figure 7A and 8A) and then each set of 
cells was separately transfected with pcDNA3.1-PP4c and pcDNA3.1. Viable 
cell count was determined by vital dye staining and apoptosis by annexin V 
and flow cytometry after 48 h. (A) and (B) Over-expression of PP4c in MCF7 
cells transfected with (-) siRNA causes a reduction in viable cell number and 
an increase in apoptosis compared to cells transfected with pCDNA3.1. 
PEA15 specific siRNAs causes a reduction in MCF7 viable cell number and 
increase in apoptosis. PP4c over-expression in these cells does not cause 
additional loss of viable cell number nor an increase in the proportion of 
apoptotic cells. (C) and (D) MDA-MB-231 cells transfected with specific 
PEA15 siRNAs shows a significant reduction in viable cell number compared 
to cells transfected with (-)siRNA. PP4c over-expression results in a reduction 
in the number of viable cells and increase in the percentage of apoptotic cells 
in the cells transfected with (-)siRNAs and has no additional effects on the 
cells transfected with PEA15 siRNAs. Data are presented as the means ± 
SEM from four independent experiments. *P< 0.05 compared to pcDNA3.1 
(one-way ANOVA and Bonferrroni's MCT).  
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